GENFIT (GNFT)
(Delayed Data from NSDQ)
$3.76 USD
+0.02 (0.54%)
Updated May 10, 2024 03:45 PM ET
3-Hold of 5 3
C Value F Growth D Momentum D VGM
Brokerage Reports
0 items in cart
GENFIT S.A. Unsponsored ADR [GNFT]
Reports for Purchase
Showing records 41 - 60 ( 114 total )
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Market Shudders But We See Names to Outperform.
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
NASH Weekly: Our Thoughts on Seladelpar and Readthrough to Elafibranor
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Short Delay of Pivotal Data Is a Net Positive to Allow for FDA Feedback; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Do Not Forget to Dial-in to Our NASH Call Today with Dr. Arun Sanyal at 1PM
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Yas Weekly Recap of Our Key Notes and 9 Doc Calls Upcoming in 1H20
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Our NASH Expert Call with Dr. Arun Sanyal Moved to Friday, Feb. 21, at 1PM ET
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Do Not Forget to Dial-in to Our Call Today with Dr. Arun Sanyal at 12pm
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Data-Driven Analysis to Figure out POS of RESOLVE-IT - Must Read
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Healthcare - Can''t Miss Takeaways from our NASH Fibrosis Expert Call with Dr. Scott Friedman
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Join our Part 2 NASH Call on Feb. 18 with Dr. Arun Sanyal
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Do Not Miss Our NASH Fibrosis Call with Dr. Scott Friedman at 12pm ET
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Dial In to Part 1 of Our Three-Part NASH Call Series Tomorrow at 12PM
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Revisit NASH in 2020: Join Our Three-Part Call Series
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Healthcare -Join Our 1Q20 Doc Call Series in PWS, NASH, Omega-3s and Contraception
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Healthcare- Yas'' Weekly Recap of Our Key Notes and Upcoming Events
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
NASH Weekly: 2020 Is Packed With Clinical Data Readouts in NASH
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: GENFIT S.A. Unsponsored ADR
Industry: Medical - Biomedical and Genetics
NASH Weekly: GLP-1 Data in 2Q20 Is Likely to Be Underwhelming
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y